NuPulse Announces Physician Call on the NuPulse Voyage™ for Chronic Heart Failure - The First Minimally Invasive, Ambulatory Option That Allows Discharge Home
- Leading cardiologists discuss promising clinical trial results, advantages of innovative investigational treatment option and large unmet need
- Pivotal trial upcoming
RALEIGH, N.C., March 13, 2025 /PRNewswire/ -- NuPulse, a medical device company focused on transforming the treatment of chronic heart failure, today announced highlights from a recent call featuring physician thought leaders discussing the NuPulse Voyage™ heart pump, a minimally invasive heart pump for chronic heart failure patients. During the webcast, physicians highlight clinical results to date, market opportunity and upcoming pivotal trial design for the NuPulse Voyage.
Participants in the NuPulse Physician Call included:
- Dr. A. Reshad Garan, Section Chief Heart Failure, Beth Israel Deaconess Medical Center;
- Dr. Robert Lee Jobe, Medical Director, Cardiac Cath Lab, UNC Rex, Raleigh NC;
- and Dr. Valluvan Jeevanandam, Director of the Heart and Vascular Center, University of Chicago Medicine and co-founder of NuPulse.
Highlights of topics and comments from the webcast include:
The need for a new treatment option for chronic heart failure patients:
"I think there's a lot of patients that would benefit from support with NuPulse, either as a bridge to recovery or being supported hemodynamically as a bridge to their next step," said Dr. Garan.
The potential benefits of NuPulse Voyage:
"What sets NuPulse apart is that it is a device that is specifically designed exactly for use as a long term, interactive modality," noted Dr. Jobe.
The NuPulse Voyage difference:
"The real beauty of this device is the complete flexibility and versatility that you have…in the hospital setting but more importantly at home as well," commented Dr. Jeevanandam.
Access Webcast
An archived replay of the NuPulse Physician Thought Leader Call can be accessed here or by visiting www.nupulse.com.
About the NuPulse Voyage™
The NuPulse Voyage is the only cardiac assist device for chronic heart failure implanted in a minimally invasive manner that allows the patient to ambulate and be discharged home with the device in place. Following completion of a successful feasibility trial, NuPulse is preparing for launch of a pivotal trial to support NuPulse Voyage market approval.
Featured Publication
Preliminary results from the NuPulseCV feasibility study were published in the American Heart Association Journal Circulation: Heart Failure: "Clinical Outcomes and Quality of Life with an Ambulatory Counterpulsation Pump in Advanced Heart Failure Patients."
About NuPulse
NuPulse is a privately held company focused on the development of innovative treatment options to radically impact treatment and outcomes for patients with chronic heart failure. The company's patented device, the NuPulse Voyage, has completed a positive feasibility study and is poised to enter a pivotal trial to support product approval. NuPulse is headquartered in Raleigh, NC.
For more information, please visit www.nupulse.com and follow the company on LinkedIn @NuPulse.
Contact:
Investors & Media
Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com
206-769-9219
View original content to download multimedia:https://www.prnewswire.com/news-releases/nupulse-announces-physician-call-on-the-nupulse-voyage-for-chronic-heart-failure--the-first-minimally-invasive-ambulatory-option-that-allows-discharge-home-302400793.html
SOURCE NuPulse